Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI - Get Free Report) traded down 1.5% during mid-day trading on Friday . The company traded as low as $4.40 and last traded at $4.56. 91,031 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 1,049,645 shares. The stock had previously closed at $4.63.
Virios Therapeutics Stock Performance
The firm has a fifty day moving average of $5.29 and a 200 day moving average of $4.92. The firm has a market capitalization of $87.82 million, a PE ratio of -16.89 and a beta of 1.58.
About Virios Therapeutics
(
Get Free Report)
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Virios Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Virios Therapeutics wasn't on the list.
While Virios Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
